Mrsa | Vancomycin Dominates As First-Line Defense Against MRSA Infections


Vancomycin, which has experienced increased usage over the past five years, continues to dominate as a first-line treatment of MRSA infections, according to a Decision Resources and Arlington Medical Resources news release.

AMR analyzed survey data from infectious disease specialists and internists as well as hospital patient-level medical data. Sixty to 76 percent of surveyed infectious disease specialists indicated that they use vancomycin as first-line treatment for bloodstream infections, complicated skin and skin structure infections and hospital-acquired pneumonia suspected to or confirmed to involve MRSA.


Results also showed surveyed infectious disease specialists consider sepsis and prosthetic joint infections to be the most difficult-to-treat indications needing novel anti-MRSA therapies. Additionally, patient-level audit data of drug costs


Click here to view rest of article from original site

Giant Microbes Mrsa (multiple-resistant Staphylococcus Aureus) Gigantic Giant Microbes Mrsa (multiple-resistant Staphylococcus Aureus) Gigantic
oll  by Giant Microbes
Vetericyn Wound & Infection Treatment  by Vetericyn Vetericyn Wound & Infection Treatment  by Vetericyn

18 new from $29.75



Facebook Twitter Email